Baptist Medical Center is a hospital and a part of the Baptist Health System in San Antonio, Texas. Methodist Hospital was established in 1924 and apart of the Baptist Health System. The hospital offers San Antonio's only heart transplant program.
Abstract Objective This Monte Carlo simulation study examined whether neuropsychological test battery length impacts cognitive impairment classification accuracy using actuarial and Bayesian interpretive frameworks. Three hypotheses were tested: (a) longer batteries yield higher false-positive rates due to cumulative probability effects; (b) longer batteries show superior classification accuracy; and (c) abbreviated batteries have higher false-negative rates. Method Four simulated batteries of varying length, domain coverage, and redundancy were applied to 10,000 virtual patient profiles. Sensitivity, specificity, predictive values, classification accuracy, and Bayesian post-test probabilities were evaluated across multiple prevalence conditions alongside base rates of low scores and resource demands. Results Hypothesis 1 was supported: longer batteries produced higher base rates of low scores in healthy controls. However, applying actuarial and Bayesian frameworks prevented this from translating into inflated false-positive rates. Hypotheses 2 and 3 were not supported: abbreviated batteries maintained classification accuracy, discrimination (AUC), false-negative rates, and predictive values comparable to longer batteries. Adding tests yielded diminishing returns, reaching a psychometric plateau at approximately eight tests. Conclusions Battery length does not meaningfully alter binary impairment classification when actuarial and Bayesian rules are applied. Brief core batteries maximize efficiency for global detection, while comprehensive batteries remain best suited for detailed cognitive profiling and differential diagnosis.
BACKGROUND:Dalbavancin is a long-acting lipoglycopeptide commonly used off-label to treat deep-seated infections. An emerging potential niche for dalbavancin is suppressive antibiotic therapy (SAT), for which data remain limited. OBJECTIVE:This study aimed to characterize real-world dalbavancin dosing strategies for SAT and assess associated safety and efficacy outcomes. METHODS:This was a multicenter, multinational, retrospective, single group, descriptive study among adult patients who received at least 1 dose of dalbavancin SAT between January 1, 2018, and March 31, 2023, excluding dalbavancin doses administered for treatment of active infection. The primary endpoint was to describe dalbavancin dosing strategies for SAT. Additional endpoints included treatment-emergent adverse events (TEAEs) and clinical failure. RESULTS:Forty-six patients received dalbavancin SAT for a median of 201 days (IQR, 84-313). Most patients (83%, n = 38) had a retained prosthesis or device. Most infections were monomicrobial with Staphylococcus spp. being the most prevalent pathogen (63%, n = 29). The most frequent dosing was 1500 mg IV every 2 weeks. Treatment-emergent adverse events were observed in 21 (45.7%) patients, with acute kidney injury being the most common (32.6%, n = 15). One (2.2%) TEAE, nausea, led to discontinuation or modification. Eight patients (17.4%) experienced clinical failure, defined as hospitalization or microbiological recurrence due to index pathogen, after a mean duration of 7 months. CONCLUSION AND RELEVANCE:This multicenter cohort included the largest sample size of dalbavancin SAT to date, employed across diverse infections with substantial heterogeneity in dosing strategies. Clinical failure was observed in a minority of patients and discontinuation due to adverse events was uncommon. Laboratory abnormalities, including acute kidney injury, were observed but were rarely attributed directly to dalbavancin. These findings suggest dalbavancin may represent a practical suppressive therapy option when oral agents are not feasible, though further studies are needed to define optimal dosing strategies and long-term safety.